Spotlight On... Apellis pulls its IPO as biotech bears rampage on Wall Street; Sanofi names Gilead development exec as new head of BD; Sanofi will accelerate Zika vaccine development; and more...

Editas ($EDIT) and BeiGene ($BGNE) may have made it to Nasdaq, but the IPO window isn't open for everyone. Apellis pulled their attempt at going public. The Kentucky biotech had filed for an $86 million offering last fall, as the market began to unwind. Analysts expect that the bar for completing an IPO of any kind has been raised high in the first half of 2016, as biotech shares in particular have come in for a beating. Story

@FierceBiotech: Amplyx ups its B round to $49.2M on the way to the clinical with an antifungal drug. Article | Follow @FierceBiotech

@JohnCFierce: Are the big M&A players in biopharma (like Sanofi/Gilead/Biogen) waiting out the bear market? More | Follow @JohnCFierce

@DamianFierce: Thesis of this BIO thing is that you can't put $ on life, but doesn't pricing onco drugs based on OS do just that? | Follow @DamianFierce

> Sanofi ($SNY) has turned to the deal master at Gilead ($GILD) to help it with its next round of negotiations. Muzammil "Muz" Mansuri, the SVP of corporate development at Gilead, is joining the pharma giant's executive board and taking the post of EVP of strategy and business development at Sanofi. Release

> Sanofi's Olivier Brandicourt says that the company will press hard to shorten the development of a new vaccine for the Zika virus to three years. Story

Medical Device News

@FierceMedDev: Sientra resumes U.S. sales of breast implants after Brazil manufacturing fallout. Report | Follow @FierceMedDev

@EmilyWFierce: ICYMI from FiercePharma: PhRMA kicks off new ad campaign to doctor pharma's tarred image. Article | Follow @EmilyWFierce

> BTG, Philips roll out first cancer embolic bead visible via real-time imaging. Report

> CMS backtracks, gives Boston Sci favorable reimbursement for its stroke-fighting Watchman. Article

Pharma News

@FiercePharma: Omega diet-aid ad banned in U.K.; summer slimming promos not 'socially responsible.' FiercePharmaMarketing article | Follow @FiercePharma

@CarlyHFierce: All I want is to hear two people pronounce "Praluent" the same way. $REGN | Follow @CarlyHFierce

> Top Senate Democrat grills HHS about opioid panel's alleged ties to industry. Article

> Sanofi's outlook less than sunny as key diabetes franchise continues to sag. Report

Pharma Manufacturing News

> Plant to manufacture yellow fever jab slated for Dakar. More

> FDA quality focus will definitely mean winners and losers, report says. Report

> Dr. Reddy's grows U.S. sales even in face of FDA action. Story

> Report says CMOs without U.S. facilities risk being left out of 'hot' market. Item

> Strides Shasun deals adds seventh plant to its African production network. Article

Pharma Asia News

> China Resources Pharmaceutical plans HK IPO. News

> Taiwan's outgoing leader touts biotech growth. Story

> Japan's Eisai surprises with API move. Item

> Japan continues to see generics as way to ease healthcare costs. Report

> Novo says China price pressures may go into 2017. Article

Drug Delivery News

> 'Crystal balls' in drug delivery could be stronger than liposomes. More

> Novartis signs with France's MedinCell for controlled-release injection tech. Story

> FDA says drug delivery devices need human factors validation testing. Item

> Struggling Unilife extends negotiating period with Amgen over partial takeover. Report

> Scilex aims to dethrone Endo in billion-dollar pain subsegment using novel transdermal patch. Article

Suggested Articles

Almirall is pulling the trigger on an option to advance Dermira's lebrikizumab in Europe, a program it reckons could rake in €450 million.

Acer Therapeutics’ stock plummeted more than 78% premarket this morning on news that the FDA had rejected approval of its drug Edsivo (celiprolol).

The latest setback prompted Novartis-partnered Conatus to lay off 40% of its staff and begin looking for strategic alternatives.